Adaptimmune Therapeutics PLC

ADAPY Healthcare Biotechnology

Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024.

Revenue
−89.3%
EPS
−140.7%
Free cash flow
−174.7%

Quarter to June 2025, against a year earlier

0.02 0.00 0.00%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−23.33
Beneish M
16.71
Dividend safety
n/a
Older periods Dec '24 Mar '25 Jun '25 Dec '25
ROE

+8 more TTM periods

(273.57%) 1,087.18% (1,349.52%) —
Piotroski F-Score
3 2 0 —
ROA
(27.17%) (34.11%) (75.53%) 0.00%
ROIC
0.00% 0.00% 0.00% —
Return on Tangible Assets
(46.83%) (86.91%) (311.98%) —
Average Days of Receivables
29.49 8.90 52.23 —
Free Cash Flow per Share
(0.30) (0.43) (0.73) —
Free Cash Flow
(75.11) (109.83) (191.67) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026